The anti-inflammatory feature of glucagon-like peptide-1 and its based diabetes drugs-Therapeutic potential exploration in lung injury  

作　　者：Juan Pang Jia Nuo Feng Wenhua Ling Tianru Jin 

机构地区：[1]Department of Nutrition,School of Public Health,Sun Yat-sen Universitynstitute,Guangzhou 510080,China [2]Division of Advanced Diagnostics,Toronto General Hospital Research I,University Health Network,Toronto M5G 1L7,Canada [3]Department of Physiology,Faculty of Medicine,University of Toronto,Toronto M5S 1AI,Canada [4]Banting and Best Diabetes Centre,Faculty of Medicine,University of Toromto,Toronto M5G 2C4,Canada

出　　处：《Acta Pharmaceutica Sinica B》2022年第11期4040-4055,共16页药学学报（英文版）

基　　金：supported by the Canadian Institutes of Health Research (PJT159735 to Tianru Jin, Canada);supported by China Scholarship Council;supported by Ontario Graduate Scholarship (OGS) Program and the Banting & Best Diabetes Centre (BBDC)-Novo Nordisk Studentship

摘　　要：Since 2005,GLP-1 receptor(GLP-IR)agonists(GLP-IRAs)have been developed as therapeutic agents for type 2 diabetes(T2D).GLP-IR is not only expressed in pancreatic islets but also other organs,especially the lung.However,controversy on extra pancreatic GLP-IR expression still needs to be further resolved,utilizing different tools including the use of more reliable GLP-IR antibodies in immune-staining and co-immune-staining.Extra-pancreatic expression of GLP-IR has triggered extensive investigations on extra-pancreatic functions of GLP-1RAs,aiming to repurpose them into therapeutic agents for other disorders.Extensive studies have demonstrated promising anti-infammatory features of GLP-IRAs.Whether those features are directly mediated by GLP-IR expressed in immune cells also remains controversial.Following a brief review on GLP-1 as an incretin hormone and the development of GLP-IRAs as therapeutic agents for T2D,we have summarized our current understanding of the antiinflammatory features of GLP-IRAS and commented on the controversy on extra-pancreatic GLP-IR expression.The main part of this review is a literature discussion on GLP-IRA utilization in animal models with chronic airway diseases and acute lung injuries,including studies on the combined use of mesenchymal stem cell(MSC)based therapy.This is followed by a brief summary.

关 键 词：Anti inflammation EXENATIDE GLP-1R GLP-1RAs LIRAGLUTIDE Lung injury MSC-based therapy TxNIP 

分 类 号：R977.15[医药卫生—药品]